CD44 and glioblastoma: We then used two shRNA-IGFBP2 clones (IGFBP2KD) or an anti-IGFBP2 antibody (anti-IGFBP2) directly to inhibit IGFBP2 in mouse GBM cells (GL261 cells) and found that mesenchymal marker proteins [25, 26] fibronectin, CD44, and vimentin were correspondingly markedly decreased compared to the control (Fig 1B and 1C, * p < 0.05, ** p < 0.01, *** p < 0.001).